Characterization of β-adrenoceptor subtypes in the ferret urinary bladder in vitro and in vivo

被引:19
作者
Takeda, H [1 ]
Igawa, Y
Komatsu, Y
Yamazaki, Y
Akahane, M
Nishizawa, O
Ajisawa, Y
机构
[1] Kissei Pharmaceut Co Ltd, Cent Res Lab, Hotaka, Nagano 3998304, Japan
[2] Shinshu Univ, Sch Med, Dept Urol, Matsumoto, Nagano 3908621, Japan
关键词
beta-adrenoceptor; subtype; (ferret); detrusor; cardiovascular system;
D O I
10.1016/S0014-2999(00)00586-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, the beta-adrenoceptor subtypes distributed in the detrusor of the ferret were investigated in functional experiments in vitro and in vivo using a variety of beta-adrenoceptor agonists and antagonists. All the beta-adrenoceptor agonists tested relaxed the isolated detrusor strip, the rank order of potency being (+/-)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]phenoxy]-acetic acid sodium (BRL 37344A) > (+/-)-4-(3-t-butylamino-2-hydroxypropoxy) benzimidazol-2-one (CGP-12177A), isoprenaline and (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethylamino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243) > dobutamine and procaterol. In antagonist experiment, 3-(2-allylphenoxy)-1-[(1S)-1,2,3,4-tetrahydro-naphth-1-ylamino]-(2S)-2-propanol hydrochloride (SR 58894A), but neither 2-hydroxy-5(2-((2-hydroxy-3-(4-((1-methyl-4-trifluoromethyl)1H-imidazole-2-yl)-phenoxy)propyl)amino)ethoxy)-benzamide monomethane sulphonate (CGP-20712A) nor erythro-(+/-)-1-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol hydrochloride (ICI-118,551), caused a rightward shift of the concentration-relaxation curve for isoprenaline. In in vivo experiments, isoprenaline and CL 316,243 each reduced bladder pressure in a dose-dependent manner. CL 316,243 was the only drug that did not produce any significant influences on blood pressure and heart rate at doses that reduced bladder pressure. The present functional study provides the first evidence that relaxation of the ferret detrusor by beta-adrenoceptor activation is mediated mainly via the beta(3)-adrenoceptor, as in the human detrusor. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 30 条
[1]   Advances in the pharmacological control of the bladder [J].
Andersson, KE .
EXPERIMENTAL PHYSIOLOGY, 1999, 84 (01) :195-213
[2]   THE BROWN ADIPOCYTE BETA-ADRENOCEPTOR [J].
ARCH, JRS .
PROCEEDINGS OF THE NUTRITION SOCIETY, 1989, 48 (02) :215-223
[3]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[4]   In vitro inhibition of human colonic motility with SR 59119A and SR 59104A:: evidence of a β3-adrenoceptor-mediated effect [J].
Bardou, M ;
Dousset, B ;
Deneux-Tharaux, C ;
Smadja, C ;
Naline, E ;
Chaput, JC ;
Naveau, S ;
Manara, L ;
Croci, T ;
Advenier, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) :281-287
[5]   DISTRIBUTION OF BETA(3)-ADRENOCEPTOR MESSENGER-RNA IN HUMAN TISSUES [J].
BERKOWITZ, DE ;
NARDONE, NA ;
SMILEY, RM ;
PRICE, DT ;
KREUTTER, DK ;
FREMEAU, RT ;
SCHWINN, DA .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 289 (02) :223-228
[6]   DISODIUM (R,R)-5-[2-[[2-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMINO]PROPYL]-1,3-BENZODIOXOLE-2,2-DICARBOXYLATE (CL 316,243) - A POTENT BETA-ADRENERGIC AGONIST VIRTUALLY SPECIFIC FOR BETA-3 RECEPTORS - A PROMISING ANTIDIABETIC AND ANTIOBESITY AGENT [J].
BLOOM, JD ;
DUTIA, MD ;
JOHNSON, BD ;
WISSNER, A ;
BURNS, MG ;
LARGIS, EE ;
DOLAN, JA ;
CLAUS, TH .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) :3081-3084
[7]  
BYLUND DB, 1994, PHARMACOL REV, V46, P121
[8]   FUNCTIONAL EVIDENCE FOR THE PRESENCE OF BETA(3)-ADRENOCEPTORS IN THE GUINEA-PIG COMMON BILE-DUCT AND COLON [J].
DEPONTI, F ;
GIBELLI, G ;
CREMA, F ;
LECCHINI, S .
PHARMACOLOGY, 1995, 51 (05) :288-297
[9]  
DePonti F, 1996, BRIT J PHARMACOL, V117, P1374
[10]   Alternative splicing generates two isoforms of the β3-adrenoceptor which are differentially expressed in mouse tissues [J].
Evans, BA ;
Papaioannou, M ;
Hamilton, S ;
Summers, RJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (06) :1525-1531